Summary: Convection-enhanced delivery (CED) of substances within the human brain is becoming a more frequent experimental treatment option in the management of brain tumors, and more recently in phase 1 trials for gene therapy in Parkinson's disease (PD). Benefits of this intracranial drugtransfer technology include a more efficient delivery of large volumes of therapeutic agent to the target region when compared with more standard delivery approaches (i.e., biopolymers, local infusion). In this article, we describe specific technical modifications we have made to the CED process to make it more effective. For example, we developed a reflux-resistant infusion cannula that allows increased infusion rates to be used. We also describe our efforts to visualize the CED process in vivo, using liposomal nanotechnology and real-time intraoperative MRI. In addition to carrying the MRI contrast agent, nanoliposomes also provide a standardized delivery vehicle for the convection of drugs to a specific brain-tissue volume. This technology provides an added level of assurance via visual confirmation of CED, allowing intraoperative alterations to the infusion if there is reflux or aberrant delivery. We propose that these specific modifications to the CED technology will improve efficacy by documenting and standardizing the treatment-volume delivery. Furthermore, we believe that this image-guided CED platform can be used in other translational neuroscience efforts, with eventual clinical application beyond neuro-oncology and PD.
INTRODUCTION
Delivery of therapeutic agents into the brain has been an ongoing challenge to clinicians and scientists for many years. Intravascular administrations of therapeutic agents have been confounded by the efficiency of the blood-brain barrier (BBB) 1 that allows entrance of molecules based on size, lipid solubility and charge, 2, 3 severely limiting entry of charged small molecules or larger compounds such as proteins or viral particles. Disruption of the BBB has been used clinically to temporarily broach this natural barrier between the brain and the vascular system, 2,4 allowing a greater quantity and variety of intravascular therapeutic agents to access the brain parenchyma, including monoclonal antibodies and radio-immunoconjugates. 5, 6 This technology has been successful in the treatment of many neuro-oncologic conditions in a number of centers, 7 and especially with primary central nervous system (CNS) lymphoma. 8 Unfortunately, despite selective opening of unilateral or bilateral vertebrobasilar or carotid cerebrovascular distributions via the arterial approach, controlling the region of treatment through this technique remains complicated and limited to a major vascular distribution. In addition, repeated treatments add to patient discomfort and potential morbidity, ultimately narrowing the clinical use of osmotic BBB disruption therapy.
Neurosurgeons have been circumventing the BBB for decades via more direct approaches to the brain parenchyma and cerebrospinal fluid spaces. In many cases of brain tumor, therapeutic materials have been placed within the adjacent brain or tumor bed after resection. 9 Various catheters/cannulae have been stereotactically placed into the brain or CSF spaces for more precise delivery of therapeutic compounds in cases of tumor, 10 -12 and more recently PD. 13, 14 Biopolymer tech-nology has allowed chemotherapeutic agents to be placed and gradually released at the brain surface subsequent to tumor resection, providing higher local concentrations than possible via systemic delivery, without the associated systemic toxicity. [15] [16] [17] Depending on the biopolymer composition, drugs can be delivered in a controlled manner for a finite period of time. Unfortunately, reoperation is required for re-dosing of the patient with these biopolymers, and controversy remains over cost and associated morbidities. Catheter techniques allow repeated dosing at the specific site of catheter placement, usually without significant discomfort or morbidity for the patient, especially when coupled with subcutaneous reservoirs or mini-pumps. 18, 19 Through these techniques, the BBB is bypassed, allowing the specific therapeutic agent direct access to the brain parenchyma and CSF. Unfortunately, because all of these modalities depend on diffusion of their treatment materials from the source (i.e., biopolymer, catheter openings), as previously noted in preclinical studies, the diffusion distance is limited to the immediate (several mm) surrounding brain volume. 17 Diffusion is linked directly to the concentration gradient and diffusion coefficient of the molecule, with molecular size having an inverse relationship with diffusion. 20 -22 Limits to diffusion of more than several millimeters for low molecular weight compounds include capillary clearance and, in some cases, metabolism. [23] [24] [25] To date, treatments using these diffusion technologies remain difficult to standardize due to lack of control of the diffusion and the associated heterogeneity of distribution of the therapeutic substances due to some of the factors previously described. In addition, the extent of diffusion in vivo is difficult to confirm, making any treatment standardization and comparisons difficult at best, and usually impossible.
Convection-enhanced delivery (CED) technology offers the clinician a more specific option in delivering therapeutic agents to a larger and more consistent treatment volume than the standard diffusion-based technologies. CED uses bulk flow of the therapeutic material through the extracellular space of the tissue. 26 Bulk flow distributes therapeutic agents homogeneously within a controlled brain volume, regardless of molecular size, with a steep concentration drop at the advancing margin of the bulk flow. This fact opens the door to convection of viral particles (for gene therapy) and large macromolecules (e.g., growth factors) into the brain, in addition to other substances. The volume in which a particle (i.e., drug, virus or growth factor) distributes with CED in the brain is primarily the function of infusion rate and specific tissue characteristics. These brain tissue characteristics and CED have been modeled in animals, 27, 28 and have recently been evaluated in human brain tumor trials.
12,29 CED infusion information is now commercially available for neuro-oncology as a treatment software algorithm developed by BrainLAB through their iPlan Flow software (www.brainlab.com) (BrainLAB AG, Feldkirchen, Germany), which was approved by the Food and Drug Administration. This program essentially allows the planning of drug (or therapeutic material) delivery into the human brain based on the MRI data and brain tissue characteristics of the individual patient. Treatment of specific tumor volumes can be preplanned in three-dimension 28 (based on various infusion catheter positions) in an effort to maximize tumor coverage with the least number of catheters, in a manner similar to isodose planning for stereotactic radiosurgery. 30 Although this computer technology allows very reliable planning of treatment based on accumulated brain MRI data, it does not give the neurosurgeon real-time visualization of the CED infusion process and has yet to be fully, clinically validated in real-time with a co-convected tracer. Visualizing the CED process has recently been retrospectively carried out in patients with gliomas, using radiolabelled albumin coinfused with a cytotoxin, 31, 32 and using gadolinium diethylene triamine pentaacetic acid (DTPA) coinfusion for brainstem lesions. 33 Although the former studies 31, 32 did not allow real-time adjustment of the CED procedure and relied on a delayed analysis of nuclear medicine imaging studies overlayed on MRI images, the latter study 33 documented the potential for real-time MRI imaging in clinical situations in which the extent of delivery and possibility of leakage are most critical. Despite some continued limitations, these CED planning techniques are being used as part of our experimental neuro-oncologic studies 34 and also in clinical neurosurgery. 35 A common problem with infusions of a drug into the brain, both with injection techniques and CED, has been reflux along the catheter/cannula track. This is critical in CED because reflux prevents continued pressure in the extracellular space that drives the bulk fluid flow away from the catheter that helps determine the eventual distribution volume. 26 Once reflux develops (FIG. 1) around an infusion or CED catheter/cannula, there is a plateau to the volume of distribution (Vd) while the volume infused (Vi) increases, and the difference is lost as reflux. This reflux and lack of increase in Vd indicates preferential flow of additional Vi along the catheter/cannula tract, away from the treatment region (e.g., tumor, subthalamic nucleus, or striatum) and usually into the CSF. This is especially important in trying to avoid local or systemic toxicities associated with infused materials and to help standardize treatment protocols based on infused volumes. In a recent clinical study sponsored by Amgen (Thousand Oaks, CA), high doses (15 g/day) of glialderived neurotrophic factor (GDNF) were chronically infused into the putamen of 17 PD patients for at least 6 months. 36 Although efficacy has not been shown for this treatment protocol, 3 of these patients developed anti-bodies to the GDNF, probably due to systemic exposure of the infused protein through reflux into the CSF and the venous system. Although it is clear that many unresolved issues exist in this and other infusion studies, major areas of potential technical refinement include: 1) optimal drug dose, 2) infusion volume, 3) infusion rate, 4) catheter design and 5) prevention of reflux.
One of our goals has been to more clearly define and solve the technical problems related to CED infusion therapies that would eventually open the technology to applicability in a wide variety of clinical situations. With our concentration in neuro-oncology and PD, our CED efforts progressed in both of these areas and have recently been translated to human clinical trials (see description as follows).
CED has been the method of choice for therapeutic agent delivery in our laboratory for many years. Through studies in rats, dogs and nonhuman primates, it became obvious that CED offered the capabilities that we were looking for in scaling up our experimental treatment volumes to approach those in the human brain. Determination of appropriate drug or therapeutic agent doses remains overly complex for this discussion and requires individual assessment and clinical trials for more definitive answers. Infusion volumes with CED are usually determined by the proposed clinical target size (i.e., tumor volume or brain target volume). The relationship between the Vi and Vd is linear, but the slope (Vd/Vi) of the curve is dependent on structural properties of the tissue, such as degree of myelination 37 or the characteristics of the infusate. 26, 37 As previously noted (see previous BrainLAB discussion), specific tissue data to predict optimal infusion volumes and other measurements (e.g., catheter location) to cover the proposed Vd have been determined and allow clinical planning prior to CED infusion. Vd can be enhanced for some therapeutic agents (without increasing Vi) through the manipulation of physiologic measurements (i.e, blood pressure/heart rate) 38 and the use of heparin coinfusion. 39 An optimal infusion rate for CED has been elusive because it is often limited by the development of reflux along the cannula track. In most cases, the optimal infusion rate is that which allows the delivery of the therapeutic volume over the least amount of time without associated reflux. With all catheters/cannulas, reflux can be induced if the infusion rate is too high. The larger the catheter diameter, the more easily reflux can be induced. We, 40 along with others, 27, 41, 42 have documented that CED infusion flow rates less than 0.5 L/min may be necessary to prevent reflux in catheters up to 0.6 mm (outer diameter [OD] ). However, in a recent phase III trial of transferrin-CRM107 (Xenova Biomedix Ltd, Guilford, Surrey, UK) in glioblastoma, investigators used a ventriculo-peritoneal shunt catheter (2.5 mm OD) at a flow rate of 3.3 L/min (unpublished data). In this clinical study, one could predict a significant reflux of transferrin-CRM107 into the subarachnoid space and outside the brain parenchyma, based on the prior experimental data. 27,40 -42 Communication with a trial coordinator confirmed that this has indeed been a suspected problem (S. Kunwar, personal communication). A similar issue was found with CED used to deliver IL13-PE38QQR immunotoxin (Neopharm, Waukegan, IL) in glioblastoma. A similar delivery catheter (1.4 mm OD) was used (S. Kunwar, personal communication) and MRI signal changes were noted in the catheter tracks after infusion 11 in all 14 patients in the phase I study, possibly due to reflux.
Recently, 40 we have increased the potential CED infusion rate to 5 L/min (10-fold increase) without reflux with an innovative cannula design. The new reflux-resistant, step design cannula features a 27-gauge (0.2 mm) needle with a glued-in, internal silica tubing (the differing diameters making the step) that extends beyond the end of the needle by up to 10 mm in humans and 5 mm or less in nonhuman primates or canines. The silica has an OD of 168 m and an inner diameter of 102 m. The smaller cannula design avoids tissue trauma during insertion. Pushing flow rates significantly above 5 L/min, however, can induce reflux even with this catheter ( see  FIG. 2) , and can increase the likelihood of causing local brain tissue damage. 40 This design is being used in a phase I clinical trial at the University of California, San Francisco to deliver AAV2-hAADC (adeno-associated virus 2 carrying human aromatic amino acid decarboxylase gene) in 15 patients with moderate to severe PD (Eberling et al., manuscript submitted for publication). Since CED monitored with MRI imaging was initially described in rodents, 43 our laboratory has advanced the concept of real-time imaging of the CED process in vivo by co-infusing Gadoteridol (Prohance)-labeled (Bracco Diagnostic Inc., Princeton, NJ) neutral nanoliposomes (GDL) that are convected along with the therapeutic agent (e.g., AAV2, GDNF or CPT-11) in experimental animals, 28, 34 allowing visualization of the convection process. Neutral nanoliposomes not only carry the MRI contrast agent in this case, but also enhance the Vd of the convected material carried within the nanoliposome (i.e., drug, neurotrophic factor, viral particle) by preventing early binding of the material to the extracellular matrix or cellular lipid membranes. 37 We have shown that the Vd of the various agents carried within the neutral nanoliposomes was identical, making the nanoliposome an excellent carrier for therapeutic agents, and providing a consistent Vd profile. Drug encapsulation within liposomes allows a better Vd of lipophilic agents (i.e., ␤-chloro-nitrosourea, carmustine [Ben Venue Laboratories, Inc., Bedford, OH] and others), preventing nonspecific toxicities at local diffusion distances, while providing prolonged contact time of effective doses within significant brain tumor volumes. 44 GDL delivery of gene therapy products has shown excellent correlation between imaging and histochemical staining for the transgene (Bankiewicz et al., manuscript in preparation), providing confidence in the co-distribution of MRI contrast agent and convected therapeutic material. As previously noted, gadolinium DTPA tracer has also been used safely in a limited number of patients with brainstem lesions treated with CED. 33 Although image-guided CED requires the added costs of an intraoperative MRI scanner, and potential morbidity associated with the GDL (or other contrast agent) delivered to the brain, the time-sensitive information that this provides intraoperatively for the treating neurosurgeon is immeasurable. This is critical because we have recently noted that despite using our reflux-resistant cannula and flow rates less than 5 L/min, we documented reflux in almost 20% of the infusion tracks in both canine and nonhuman primate experimental subjects undergoing image-guided CED with GDL (Varenika et al., manuscript in review) (FIG. 2) . This real-time information allows for adjustments in treatment that could be made "on the fly" by the neurosurgeon. In some cases, reducing the infusion rate can allow effective CED to continue without reflux. More drastic changes would include adjusting the position of the infusion catheter or placing an additional catheter to cover the planned treatment volume. Without the ability to monitor CED in realtime, therefore, reflux (and Vd) cannot be accurately documented; thus real-time optimization is not possible, and treatment volumes will remain too variable to allow valid comparisons between patients in therapeutic trials. Treatment volumes may be even more critical when comparing PD patients who undergo CED gene therapy or neurotrophic factor therapy of the putamen, subthalamic nucleus, or substantia nigra. Real-time imaging and a liposomal carrier would allow visualization of the convected volume and a more reproducible Vd, despite differences in the selected therapeutic agent.
It is this wide-ranging applicability in the precise delivery of drugs, macromolecules and viral particles that encourages us to continue the development of this CED technology. What is abundantly clear to us at this stage is that the many optimizations of CED that we have worked out in animal experiments and have translated to human trials will be advanced even further through the use of a real-time, image-guided CED platform to more precisely deliver therapeutic materials into the brain. We also predict the use of this technology beyond neuro-oncology and PD, for the treatment of other neurological diseases. 
